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Doxorubicin (DOX) is a potent anti-tumoral agentwidely used for cancer therapy. Despite numerous 
studies,the fluorescence properties of DOX, usually exploited for the characterization ofthe interaction 
with biological media,have until now led to controversial interpretations, mainly due to self-association of 
the drug in aqueous solution. We present here thefirst femtosecond study of DOX based on measurements 10 
with fluorescence up-conversion technique in combination with time-correlated single photon counting 
using the same laser source. We provide evidence that fluorescence signals of DOX stem from monomers 
and dimers. DOX dimerization induces a dramatic decrease in the fluorescence quantum yield from 
3.9×10-2 to 10-5associated to the red shift of the fluorescence spectrum by ca ~25 nm.While the 
fluorescence lifetime of themonomer is 1 ns, the dimer fluorescence is found to decay with a lifetime of 15 
about 2 ps.In contrast to monomers, the fluorescence anisotropy of dimers is found to be negative. These 
experimental observations are consistent with an ultrafastinternal conversion (<200 fs) between two 
exciton states, possibly followed by a charge separation process. 
 
1. Introduction 20 
Anthracycline antibiotics are very efficient anti-tumoral agents 
extensively employed in chemotherapy for the treatment of a 
large variety of cancers. Although the exact mechanism of their 
action is still not clear, theyare thought to act as inhibitors of both 
DNA replication and RNA transcription. It is generally accepted 25 
that this biological activity relies on their interactions with B-
DNA structures,1-3 through the intercalation of the anthraquinone 
moiety at the GC sequences, while the drug sugar moiety 
interacts with the minor DNA groove.4, 5Doxorubicin (DOX), 
also known as Adriamycin (Fig. 1), is a natural 30 
anthracyclinecompound which is considered to be a prototypical 
anti-tumordrug.6-9DOX consists of a tetrahydroxy-
anthraquinonechromophore with a pendant glycosyl moiety, 
representing the essential structural features of anthracyclines. 
The anthraquinonechromophore contains two hydroxyl groups 35 
respectively positioned in direct neighbourhood of the central oxo 
group. 
 Owing to its great efficacy, DOX is still widely used in clinical 
practice, in spite of the deleterious side effects mainly related to 
its cardiotoxicity. More recently, another serious problem in 40 
DOX treatment has emerged connected to the development of 
some resistant cancer cell lines.6, 7In the frame of its clinical use, 
the poor solubilityof DOX in aqueous solution is considered to be 
a serious drawback, affectingboth its transport across the cell 
membranes and its biological activity.10In this respect, the 45 
development of nano-sized drug carriersfor DOX has recently 
attracted a lot of research interest, since it may offer the right 
solutions to overcome the problems related to cytotoxicity, 
solubility and resistance.11-19 
 50 
Fig. 1 Doxorubicin (DOX) 
 In view of the design of innovative biomedical applications 
involving DOX, understanding the nature of the interactions of 
DOX with its environment,once dissolved in aqueous solution,is 
of paramount importance. In this respect, the physical properties 55 
of DOX in aqueous solution have been the object of a large 
variety of studies including UV-vis absorption, NMR, circular 
dichroism (CD) and fluorescence spectroscopy.20-28 While 
concentration dependent absorption, NMR and CD spectra are 
generally interpreted in terms ofdimer formation, there is only a 60 
limited and controversialunderstanding of the intrinsic 
fluorescence properties of the drug in solution. Aggregation is 
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known to induce a significant decrease of the fluorescence 
quantum yield attributed to the formation of non-fluorescent 
dimers.23, 27 Fluorescence of DOX in aqueous solution has been 
reported alternatively to exhibit monoexponential or 
biexponential decays.24, 28-33The origin of such bi-5 
exponentialdecays is not fully clarified and has led to various 
interpretations. The presence of two ground-state tautomers or 
two ground-state conformers differing in their inter-molecular 
hydrogen bonds with the solvent, as well as the formation of 
astrongly fluorescent photodegradation producthave been 10 
proposed.24, 32-35These contrasting interpretations prompted us to 
examine the intrinsic photophysics of DOXin aqueous solution 
prior to studying the interaction of the drug with biological 
species or nano-sized particles. The aimofthis work is to 
disentanglethe various molecular contributions to the 15 
fluorescence signals taking also into consideration the 
aggregation tendency of DOX. To this purpose, a combination of 
femto- and picosecond fluorescence techniques was used. The 
fluorescence decays, fluorescence anisotropy decays at selected 
wavelengths and time-resolved spectra have been measured for 20 
different concentrations of DOX,in aqueous solutions, at 
physiological conditions. The overall results are discussed in the 
frame of the literature on anthracyclines and their close 
derivatives.  
2. Materials and Methods 25 
2.1. Materials 
DOX (purity >95%)was purchased from ALEXIS Biochemicals 
and used without any further purification. Solutions of DOX were 
prepared in ultra-pure water delivered by a Millipore MilliQ 
system. Aqueous solutions of DOX at physiological conditions 30 
were prepared in 10 mM Tris buffer, at pH 7.4, with 1 mM 
EDTA and 50 mM NaCl. For the time resolved-fluorescence 
measurements, concentration of DOX was varied between 10 M 
and1 mM. 
2.2. Steady-statespectroscopy 35 
Steady-state absorption and fluorescence spectra were recorded 
with a double-beam UV-visible spectrophotometer (Perkin-Elmer 
Lambda 900) and spectrofluorimeter (SPEX Fluorolog-3). For 
steady-state fluorescence measurements, 1 cm thickness quartz 
cells were used. The fluorescence spectra were corrected for the 40 
wavelength-dependent response of the instrument. 
2.3. Time-resolved fluorescence measurements 
Time-resolved fluorescence measurements were carried out with 
two different techniques: time-correlated single photon counting 
(TCSPC) and fluorescence up-conversion (FU) described in 45 
detail elsewhere.36, 37In both cases, the laser source was a mode-
locked Ti-sapphire laser providing 120-fs pulses at 800 nm with a 
repetition rate of 76 MHz (MIRA, Coherent). For excitation, 
frequency-doubled pulses at 400 nm were used.For the TCSPC 
measurements, the laser repetition rate was reduced to 4.75 MHz 50 
using a pulse-picker (Coherent) and the average excitation power 
was set to less than 1 mW. The polarization of the exciting beam 
was controlled with a zero-order half-wave plate. For the FU 
measurements, the average excitation power was set to 60 mW. 
The fluorescence from the sample was collected with parabolic 55 
mirrors and mixed with the residual fundamental in a 0.5 mm 
type I BBO crystal to generate the sum-frequency light. The latter 
was spectrally filtered in a monochromator and detected by a 
photomultiplier in single-photon counting mode. The spectral 
resolution was approximately5 nm. Time-resolved fluorescence 60 
spectra in the 500-700 nm region were recorded at magic angle, 
by spectral scans on three different time scale, with time steps of 
100 fs, 1 ps and 10 ps respectively. The acquisition procedure of 
these spectra has been addressed in details in a previous report.38 
Note that the different spectral components of the up-converted 65 
signal travel at different speeds through the various optics due to 
the group velocity dispersion. Therefore,the delay stage was 
adjusted in order to compensate the wavelength-dependent 
difference in group velocity, during the spectral scans. The time-
integrated spectra were corrected a posteriorifor the spectral 70 
response of the detection, with regards to the steady-state 
fluorescence spectrum.  
 Both for TCSPC and FU, fluorescence decays were measured 
with parallel and perpendicular excitation-detection polarization 
configurations by adjusting the polarization of the excitation 75 
beam with a zero-order half-wave plate. 
 All time-resolved fluorescence measurements were performed 
at room temperature (20 ± 1°C), under aerated conditions. For 
TCSPC, the sample solution was placed in a 1 cm thick quartz 
cell and magnetically stirred.For FU, 1 mm or 2 mm thick quartz 80 
cells were used. The cell was kept rotating during acquisitions. 
Absorption and fluorescence spectra of the sample were checked 
before and after experiment. 
2.4. Data analysis 
Total fluorescence kinetics F(t) were constructed from 85 
Ipar(t)+2×G×Iperp(t), fluorescence anisotropy decays r(t) were 
calculated according to (Ipar(t) - G×Iperp(t)) / F(t). G is the ratio of 
the sensitivity of the detection system to parallel (vertical) and 
perpendicularly (vertical) polarized excitation light. In our case G 
was measured to be 1.0 for both fluorescence set-up. 90 
 Total fluorescence kinetics were independently fitted with a 
sum of exponential functions, convoluted by a Gaussian function 
representing the instrument response function. The full width at 
half maximum (FWHM) of the Gaussian was found to be about 
280 ± 15 fs at all probed wavelengths. 95 
 The rotational diffusion time Rot and the fluorescence 
anisotropy r0were extracted from the global fit of Ipar(t) and Iperp(t) 
with convolution fitting routines, following equations: 
Ipar t = 1+2*r t  *f t  
Iperp=(1-r(t) )*f(t) 
withr(t)= riexp(-t⁄τi Rot  )
m
i=1 , 
andf t =  aj*exp⁡ - t τj⁄  
n
j=1 . 100 
 The full set of kinetic profiles extracted from the time-resolved 
fluorescence spectra were globally fitted, after dimensional 
reduction and noise filtering by singular value decomposition 
(SVD),39 as previously described.40 The results of the global 
analysis are presented as Decay Associated Spectra (DAS) 105 
corresponding to the spectral distribution of the amplitudes 
associated to the time components. 
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Fig. 2Black and blue lines are the absorption coefficients of DOX 
monomers and one DOX molecule in dimers, respectively, calculated 
assuming a dimerization binding model in the analysis of a series of 
spectra obtained for varying DOX concentration.28In red, corrected 5 
steady-state fluorescence spectra (exc = 350, 400 or 450 nm) for 10 M 
DOX solution in Tris buffer.  
3. Results and discussion 
3.1. Steady-state spectroscopy of DOX and self-association 
Fig. 2 illustrates the steady-state absorption and fluorescence 10 
spectra of a 10 M DOX solution in Tris buffer at pH 7.4. These 
spectra display similar features to those of 1,4-dihydroxy 
anthraquinone (quinizarin) in protic solvents.41The absorption 
spectrum of DOX displays one main band centred at 490 nm 
associated to the 1A 1Lb transition polarized along the 15 
long axis42 anda shoulder around 360 nm attributed to partially 
forbidden n,* transitions involving the three C=O groups.22 
 The fluorescence spectrum of DOX exhibits three distinct 
peaks around 560, 594 and 638 nm associated to a vibrational 
progression with a frequency lying in the range of 1,000-20 
1,200 cm-1.21 As in the case of quinizarin, the vibrational 
structures observed in the absorption and the fluorescence spectra 
stem fromthe symmetric modes associated with the C=O bending, 
skeletal stretching and OH bending motions of the 
dihydroxyanthraquinone moiety.21, 43 25 
 The visible region of the absorption spectrum of DOX is 
known to be strongly influenced by the protonation state of the 
dihydroxyanthraquinone moiety whereasit is barely sensitive to 
the protonation state of the sugar part which is not conjugated to 
the central aromatic ring. The pKa of the daunosamine-NH3
+ 30 
group and one of the phenolic OH groups of the anthracyclinering 
B in aqueous solutionsbeing 8.15 and 10.16, respectively.44, 45 
Under physiological conditions, the phenol moietyremains 
thereforeneutral whereas the daunosamin-NH3
+ is expected to be 
positively charged for a large fraction of molecules (~82%).22, 42 35 
 Aggregation is also known to affect significantly the 
absorption spectrum of DOX leading to a slight broadening of the 
main absorption band with a significant hypochromism in the 
spectral region between 415 nm and 540 nm and a weak 
hyperchromism in the spectral region above 540 nm.20, 40 
46Literature provides quite different values for the association 
constant of DOX in aqueous solutions, depending on the 
experimental conditions.20-22, 26-28 For concentrations below5 mM, 
a simple dimerization model is in general considered sufficient to 
describe theself-association process.27Under these conditions, a 45 
previous analysis of the absorption spectra of DOX in Tris buffer, 
at physiological pH yielded a dimerization constant with log(Kd) 
= 4.8±0.1.28Using this value, it can be estimated that, a fraction of 
47% of the drug undergoesdimerization in a 10 M DOX 
solution. 50 
 The existence of dimers with two distinct geometries has been 
suggested by Agrawal et al. on the basis of the 2D NOESY NMR 
spectra of DOX in D2O and Molecular Dynamics (MD) 
calculations.27 In these two conformations, the arrangement of the 
two DOX units would consist of the stacking of the aglycone 55 
moieties either in parallel or anti-parallel orientations, with the 
methoxy substituent of D ring pointing toward the exterior or the 
interior of the interplanar space, respectively.27In the frame of the 
exciton theory, formation of such aggregates leads in principle to 
a blue shift of the absorption spectrum with regards to that of the 60 
monomeric units.47The important hypochromism at the 
absorption maximum and the concomitant hyperchromism in the 
low energy part of the absorption spectrum of dimerscould be 
explained by asignificant deviation from acollinear arrangement 
of the transition dipole moments of the two DOX units. 65 
Indeed,MD calculations predicted significant angles between the 
two aromatic planes in the parallel and the antiparallel 
conformations,respectively.27Additional indication forexcitonic 
couplingin DOX dimers has been found in the CD absorption 
spectra of the drug, at concentrationsabove 10-5 M.28Theyexhibit 70 
a characteristic excitonic bisignate doublet in the 420-580 nm 
region, from which a ~3000 cm-1Davydov splitting can be 
estimated. 
 The fluorescence quantum yield of 10 mM DOX solution for 
excitation at 480 nm is known to be 3.9×10-2.28, 33Until now, 75 
DOX dimershave been considered as “non-fluorescent” species 
whose presencenoticeably reducesthe fluorescence intensity of 
the drug solutionwithout altering the shape of the fluorescence 
spectrum.27Such a behavior provides evidence that the steady-
state fluorescence spectrum of DOX arises mainly from the 80 
monomers. At this point, it is noteworthy that, in contrast to the 
recent study of Rana et al.,33 no effect of the excitation 
wavelength on the steady-state fluorescence spectrum of DOX in 
Tris buffer, can be observed. This, a priori, discards a possible 
contribution of various ground-state species to the fluorescence 85 
signals. 
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Fig. 3(A) Typical total fluorescence decay and (B)fluorescence 
anisotropy decay of 10 M DOX in Tris buffer, at 650 nm. The red solid 
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lines correspond to fits with mono-exponential functions convoluted with 
IRF. The fit of the anisotropy was extracted from a global fit of Ipar(t) and 
Iperp(t). 
3.2. Nanosecond fluorescence decays and concentration 
effects 5 
A typical total fluorescence decay of a 10 M DOX solution 
measured by TCSPC at 650 nm is shown in Fig. 3. DOX 
fluorescence exhibits a mono-exponential decay with a lifetime of 
1 ns, independently of the emission wavelength. There is only 
weak variation of the fluorescence decays with the drug 10 
concentration. Slightly faster fluorescence decay (0.93 ns vs 1 ns) 
has been found in a 450 M DOX solution, in which 88% of the 
drug molecules undergo dimerization.Theselifetimes arein good 
agreement with recent TCSPC measurements.28, 32The 
exponential behaviour of DOX however markedly differs from 15 
some previous TCSPC measurements reporting biexponential 
fluorescence decays.24, 29-33Recently, the observation of 
biexponential decays has been correlated to the formation of 
some photodegradation products depending on the excitation 
wavelength and intensity.32 In our case, the mono-exponential 20 
fluorescence decay of DOX in Tris buffer shows that, under our 
excitation conditions, the formation of photodegradation products 
can be excluded. It also precludes the above-mentioned 
contribution of several long-lived ground-state tautomers or 
conformers to the fluorescence signals. 25 
 As illustrated in Fig. 3.B, the fluorescence anisotropy of a 
10 M DOX solutionexhibits a fast exponential decay with a time 
constant of 232±10 ps with r0 = 0.33±0.02. A similar decay has 
also been observed for a higher concentration (450 M) of DOX. 
Using the Debye-Stokes-Einstein relationship, the rotational 30 
diffusion time is given by rot =  V/kB T, where V, T and  are 
the hydrodynamic volume of DOX, the temperature and the 
viscosity of the solvent, respectively. With  = 1 cP, we estimate 
the effective volume of DOX to 938 Å3. This value is fully 
consistent with the volume of the anthracycline moiety.48Since 35 
the same anisotropy decay is observedfor the concentrated 
solution of DOX, it provides strong evidence that, in the 
nanosecond regime, the fluorescence comes from the monomers 
solely. 




































Fig. 4 Total fluorescence decays of 380 M DOX in Tris buffer,at 550, 
600 and 650 nm. The fits with a three-exponential function convoluted 
with a Gaussian representing the instrumental response function (FWHM 
280 fs) are shown by solid lines. 
3.3. Ultrafast fluorescence decays: concentration effects 45 
In the femto-picosecond regime, the fluorescence of DOX in Tris 
buffer exhibits a more complex behavior. Kinetic traces recorded 
by FU at three wavelengths are represented in Fig. 4. Individual 
FU kinetic profiles were fitted using a three-exponential function 
where the longest characteristic time was fixed to 1 ns, in 50 
accordance with the fluorescence lifetime obtained from TCSPC. 
Results of the fits are gathered in Table 1. 
Table 1. Time constants and amplitudes obtained from the individual fits 
of the fluorescence decays measured for 380 M DOX in Tris buffer.  
DOX / Tris 

























Decays were fitted using a tree-exponential function where the longest 55 
time was fixed to 1 ns. 
 As seen in Table 1, at all probed wavelengths, the fluorescence 
decays exhibits two fast components of a few hundred 
femtoseconds and about 2 ps respectively, followed bythe 
nanosecond component. The relative amplitudes (a1 and a2) of the 60 
two fast time components exhibit a clear wavelength dependence 
concomitant with a significant increase of 1 and 2 with 
wavelength. The amplitudes of thesetwo fast components 
decrease dramatically with the drug concentration. In order to 
illustrate this effect, the normalized fluorescence decays 65 
measured at 600 nm for DOX solutions at four different 
concentrations are represented in Fig. 5. The result of the 
individual fits of the fluorescence decay traces measured at 
600 nm is given in Table 2. For the highest concentrations, two 
time-constants, one sub-ps and one ranging between 1-3 ps, are 70 
needed to reproduce the fast part of the FU fluorescence decays, 
whereas for the lowest concentration (38 M), only one 
picosecond time constant suffices.This provides evidence that the 
two fast components of the fluorescence decays of DOX are 
correlated with the dimers. 75 

































Fig. 5 Typical total fluorescence decays of DOX in Tris buffer, at 600 nm 
for different concentrations of the drug. The fit with a three-exponential 
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function convoluted with a Gaussian representing the instrumental 
response function (FWHM 280 fs) are represented by the solid lines. 
Table 2. Time constants and amplitudes obtained from the individual fits 
of the fluorescence decays measured for DOX in Tris buffer, at four 
different concentrations.  5 
DOX / Tris 







































Decays were fitted using a tree-exponential function where the longest 
time was fixed to 1 ns. The fraction of monomers for each concentration 
of the drug is given in the first column. 
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Fig. 6 Typical fluorescence anisotropy decay of 800 M DOX, at 10 
600 nm.The fit of the anisotropy represented by the red solid line has 
been extracted from the global fit of Ipar(t) and Iperp(t).The dashed gray 
lines indicate the values of the anisotropy extracted from the fit (r1= -0.10 
± 0.02 and r2= 0.33 ± 0.02). 
 Fig. 6 displays the typicalfluorescence anisotropy signal 15 
recorded on a time scale of 10 ps, at all the probed wavelengths. 
As shown in Fig. 6, the anisotropy traces exhibit a ca. 6 ps rise. 
This peculiar behaviour could be explained by the superposition 
of fluorescence stemming from two different species, namely the 
dimers and the monomers. The short-lived fluorescence of the 20 
dimers is associated witha negative anisotropy (r1 = -
0.10 ± 0.02), whereas the long-lived fluorescence of the 
monomers is associated with a positive anisotropy 
(r2 = 0.33 ± 0.02), as observed in the TCSPC measurements. This 
positive anisotropy remains constant over the whole observed 25 
time interval. 
 The fluorescence anisotropy depends on the natures of the 
absorbing and emitting species (states). The negative value of the 
dimer anisotropy indicates an important electronic relaxation, on 
a time scale much faster than our time resolution (<200 fs). In 30 
other terms, the electronic transition associated with the dimer 
fluorescence is different from that associated to the photon 




(3cos2 θ -1 ) 
whereis the angle between the two transition dipoles. 
Theanisotropy of -0.1 correspond toan angle of 66°.Conversely, 35 
the high anisotropy of the monomer fluorescence shows that,in 
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Fig. 7 Time-resolved fluorescence spectra of 380 M DOX in Tris buffer 
between –0.3 and 0.2 ps (upper panel) andbetween 0.2 and 9.7 ps (lower 40 
panel). 
3.4. Origin of the ultrafast biexponential fluorescence decays 
of DOX dimers 
The short excited-state lifetime of the dimer fluorescence 
indicates the existence of non-radiative processes that are not 45 
present in the monomers. The origin of the biexponential nature 
of the dimer fluorescence decays deserves further discussion. As 
shown in Table 1, the slight increase of the two short lifetimes 
with increasing wavelength suggests a dynamical red shift of the 
fluorescence spectra of DOX on the femto-picosecond time scale. 50 
In order to confirm this hypothesis, the whole time-resolved 
spectra of DOX in Tris bufferat two different concentrationswere 
recorded. Fig. 7 illustrates the time evolutionof the spectra, over a 
time scale of 10 ps, at a DOX concentration of 380 M. It can be 
seen that the fluorescence spectrumof DOX exhibits a fast 55 
dynamical shift to the red within the duration of the apparatus 
function. Beyond a time delay of 0.2 ps, the fluorescence 
spectrum of DOX starts to decrease in intensity. After 6 ps, the 
fluorescence spectrum remains constant over the probed time 
window.  60 
 The global kinetic analysis of the time-resolved fluorescence 
spectra of DOXrequired the sum of three exponential 
components. Fig. 8 displays the corresponding DAS.Their 
associated lifetimes are 0.22 ± 0.02 ps, 1.54 ± 0.05 ps for the 
380 M DOX solution and 0.14 ± 0.01 ps, 1.45 ± 0.06 ps for the 65 
100 M DOX solution, respectively. The longer time component 
associated to the monomer fluorescence has been fixed to 1 ns, 
like for the individual fits. It is worth noting that this global 
analysis procedure, which implies a compartmental description of 
the spectro-temporal evolution of the system, is not well-adapted 70 
if the fluorescence spectra display continuous time-dependent 
spectral shifts, which is the case in the present work. Still, 
thisprocedure is judged to provide a satisfactory qualitative 
description of the time-dependentfluorescence spectrum of 
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DOX.Consequently, the global procedure can provide time 
constants thatdiffer slightly from those obtained by individual fits 














 DAS1 0.140.01 ps
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Fig. 8Decay-associated spectra DAS (solid lines) of the three time 5 
components found in the SVD analysis of the time-resolved fluorescence 
spectra of DOX in Tris buffer, at two different concentrations: 
(A)100 M and(B) 380 M.For comparison, the steady-state fluorescence 
spectrum of DOX is repesented by the blue short-dashed lines. 
 As illustrated on Fig. 8, the relative amplitudes of the two first 10 
DAS with respect to DAS3 are clearly correlated to the drug 
concentration. Both of them can therefore be ascribed to the 
spectro-temporal changes of the dimer fluorescence spectrum. 
DAS1 (0.14 and 0.22 ps, respectively) displays the characteristic 
features of a fast dynamicalStokes shift of the fluorescence 15 
spectrum of dimers causing the continuous red shift of the band. 
The positive contribution between 500 nm and 650 nm in DAS1 
arises from the fast initial decay on the blue side of 
thefluorescence band whereas the positive contribution above 650 
nm corresponds to the rise on the red side of the fluorescence 20 
band. DAS2 (~1.5 ps) and DAS3 (1 ns)illustrate the fluorescence 
decay of the dimers and the monomers, respectively.The 
fluorescence spectrum ofthe dimers (DAS2) issignificantly red-
shifted with regards to that of the monomers(DAS3).At this point, 
it is worth noting that the percentage of photons emitted by the 25 
dimers (𝑎2𝜏2/  𝑎𝑖
3
𝑖=2 𝜏𝑖 , see Table 1) corresponds toless than 
0.2% of the total fluorescence. The fluorescence quantum yield of 
the dimers is estimated to 10-5. 
 The fast dynamical Stokes shift of the dimer fluorescence in 
Tris buffercan be described by an exponential function with a 30 
time component of 0.24 ± 0.05 ps (see SI Figure S1).Such a 
shiftcan be attributed to different processes occurring on the 
femto-picosecond time scale. First, a rationale may be offered by 
solvation dynamics, which is known to produce a spectrum like 
DAS1 with a negative amplitude in the red wing.For comparison, 35 
solvation dynamics of water has been shown to involve three 
components (<1 ps), with an average time of about 0.5 ps.49-51 
The dynamical shift of the DOX fluorescence, which is mostly 
described by DAS1 (~0.2 ps), appears to be twice faster than the 
average time of the solvation dynamics of water. This could be 40 
explained by the short lifetime of dimers preventing the 
observation of the entire solvation process. Besides the solvation 
dynamics, vibrational relaxation may also contribute to the 
earliest dynamics of the dimer fluorescence (DAS1). Such a 
process would lead to a rapid narrowing of the emission band, in 45 
particular on the blue side, in agreement with the large amplitude 
decays observed around 550 nm (see Table 1). 
 The fluorescence spectrum of DOX dimers represented by 
DAS2 is found to be 25-nm red-shiftedwith respect to that of the 
monomers. From the fraction of absorbing dimers vs.monomers, 50 
it can be estimated that the transition moment associated with the 
dimer fluorescence is about 5 times smaller than that of the 
monomer. The concomitant depolarization of the dimer 
fluorescence, observed immediately after excitation,is consistent 
withthe excitationof anupper exciton statefollowed by a fast 55 
internal conversionto a lowerexciton statefrom whichemission 
arises. For this reason, the electronic transitions related to photon 
absorption and photon emission have different polarization.Note 
that the fast conversion between the two exciton states can also 
be associated to important vibrational relaxation in the lower 60 
state, in line with the above-mentioned fast decay of the blue side 
of the dimer fluorescence. 
 Due to the weakertransition moment of the dimer fluorescence, 
one would expect its fluorescence lifetime to be longer than that 
of the monomer.In contrast, the acceleration of the dimer 65 
fluorescence decay with respect to that of the monomer indicates 
the presence of additional non-radiative relaxation pathways.For 
instance, such fast excited-state decays have been reported 
inrhodamine 800 dimers.52They were attributed to the 
dissociation of the dimers in their excited-state leading to the 70 
formation of excited monomers.52Such a process is not consistent 
with our experimental observationssincenodelayed rise of the 
monomers fluorescence is observed.Alternately, fast fluorescence 
decay in bichromophoric molecules such as perylene diimide53 
and naphthalene diimides54 have been assigned to a charge 75 
separationbetween the two units. In this context, we tentatively 
assign the fast fluorescence decay of DOXdimers to a charge 
separation process,occurringon a time scale of 1-2 ps,which is 
comparable to the diffusive part of the solvation dynamics. In 
agreement with this attribution, the lifetime of DOX dimers in 80 
D2O is found to beslightly longer to that observed in Tris 
bufferand pure H2O (see SI Figures S2 and S3 andTables S1 and 
S2). Even though literature data on D2O solvation dynamics are 
scarce, the average solvation times of D2O islonger than that of 
H2O.
50, 51 85 
4. Conclusion 
In this report, we have presented the first fluorescence study of 
DOX using a combination of time-resolved techniques with a 
time resolution up to 200 fs, in order to disentangle the various 
molecular contributions to the fluorescence of the drug. 90 
Fluorescence decays of DOX in aqueous solution, at 
physiological conditions, were found to exhibit three exponential 
components whose amplitudes display a strong dependence on 
the drug concentration. The fluorescence lifetimes span from 
0.2 ps to 1 ns. The fast components in the femto-picosecond 95 
regime can be unambiguously ascribed to the fluorescence of 
DOX dimers whereas the slowest component is due to the 
monomers. 
 In contrast to some previous time-resolved fluorescence 
studies of DOX by TCSPC, we did not find any evidence of 100 
contributions of different tautomeric forms or photodegradation 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |7 
products.24, 32-35 The global analysis of the time-resolved 
fluorescence spectra of DOX, measured at two different 
concentrationsin the femto-picosecond regime, allowed the 
extraction of the fluorescence spectra associated to monomers 
and dimers. The fluorescence spectrum of monomers is similar to 5 
the steady-state fluorescence spectrum of DOX and has a lifetime 
of 1 ns. In contrast, dimers display a significantly red-shifted and 
structureless fluorescence spectrum which undergoes a fast 
dynamic Stokes shift during a few hundred femtoseconds before 
vanishing in about 2 ps. 10 
 The time-resolved fluorescence anisotropy decays provide 
evidence that the two species contribute to the fluorescence 
signals with distinct anisotropies, respectively. Dimer 
fluorescence is associated with a negative anisotropy of -0.1 
while anisotropy of monomer fluorescence is equal to 0.33. Such 15 
observation is consistent with the occurrence of a fast internal 
conversion between two excitonic states followed by a charge 
separation process leading to the fast decay of the dimer 
fluorescence. Comparative measurements in salt-rich aqueous 
solution, pure water and heavy water suggest that this latter 20 
process could bepromoted bythe solvation dynamics. 
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